ReviewPostgraduate medical journal2002
Management of motor neurone disease.
Review in Postgraduate medical journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 85 citations in OpenAlex.
- Mushroom-cage gastrostomy tube placement in patients with amyotrophic lateral sclerosis: a 5-year experience in 104 patients in a single institution.European radiology · 2009Trial
- Banking on My Voice: Life with Motor Neurone Disease.Healthcare (Basel, Switzerland) · 2025Article
- Application of Anticonvulsants, Antiepileptic Drugs, and Vitamin C in the Treatment and Analysis of Batten Disease.Cureus · 2022Review
- Strengthening the Case for Cluster Set Resistance Training in Aged and Clinical Settings: Emerging Evidence, Proposed Benefits and Suggestions.Sports medicine (Auckland, N.Z.) · 2021Article
- Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis.Neurotoxicity research · 2019Review
- Clinical and research applications of neuromuscular ultrasound in amyotrophic lateral sclerosis.Degenerative neurological and neuromuscular disease · 2019Article
- Amyotrophic Lateral Sclerosis and its Mimics/Variants: A Comprehensive Review.Journal of clinical imaging science · 2018Review
- Laryngeal response patterns influence the efficacy of mechanical assisted cough in amyotrophic lateral sclerosis.Thorax · 2017Observational
- Systems biology of neurodegenerative diseases.Integrative biology : quantitative biosciences from nano to macro · 2015Review
- Dying with motor neurone disease, what can we learn from family caregivers?Health expectations : an international journal of public participation in health care and health policy · 2014Article
- Percutaneous endoscopic gastrostomy: indications, technique, complications and management.World journal of gastroenterology · 2014Review
- Management of amyotrophic lateral sclerosis.Drugs · 2008Review
- Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management.CNS drugs · 2007Review
- Percutaneous endoscopic gastrostomy: a safe and effective bridge for enteral nutrition in neurological or non-neurological conditions.Neurocritical care · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motor neurone disease is a progressive neurodegenerative disorder leading to severe disability and death. It is clinically characterised by mixed upper and lower motor neurone involvement affecting bulbar, limb, and respiratory musculature. Recent guidelines have established diagnostic criteria and defined management of the condition. In a proportion of familial amyotrophic lateral sclerosis there is a mutation in the gene encoding the enzyme copper/zinc superoxide dismutase 1; this has allowed mutation screening and generated considerable laboratory based research. The diagnosis must be given with care and consideration and close follow up is essential. Management involves a multidisciplinary team based in the hospital and the community. Riluzole is the only drug shown to have a disease modifying effect and has been approved by the National Institute for Clinical Excellence. The essence of care is good symptomatic management, including nutritional support with percutaneous endoscopic gastrostomy and ventilatory care with non-invasive ventilation. Palliative care should be introduced before the terminal stages after careful discussion with the patient and carers. Knowledge of this condition has grown dramatically recently with a parallel improvement in treatment and ability to deal with the most troublesome problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.